Harvard Business Review

JANUARY 27, 2016

Much fanfare has been paid to the term “disruptive innovation” over the past few years. Disruptive innovations are: Cheaper (from a customer perspective). Because disruptive products were cheaper, more accessible, and built on new technology architectures, they tended to be crummier than the existing highest-end solutions.

Disruptive Innovation 8

Disruptive Innovation Innovation Short-term Long-term 8

Harvard Business Review

DECEMBER 20, 2011

The two biggest product stories of 2011 were arguably Lipitor and the iPhone 4S. The iPhone 4S's story seems to be about a new beginning: the highly anticipated launch of the latest version of a blockbuster consumer-technology product. Diplomat will sell mail-order branded Lipitor at generic prices. Both Pfizer and.

Disintermediation 16

Disintermediation Industry Pharmaceuticals Price 16

Harvard Business Review

JUNE 7, 2012

Or you could completely undercut industry pricing models by, say, 90%. You don’t cut prices by 90% through marginal improvements in existing products. If such radical price competition seems far-fetched, consider how smartphone and iPhone apps have cut the legs out from under numerous incumbents, like GPS manufacturers.

Disruptive Innovation 12

Disruptive Innovation Innovation Pharmaceuticals Class 12

Harvard Business Review

MARCH 28, 2012

The Swiss pharmaceutical giant Roche is nothing if not determined in its quest to acquire Illumina, the San Diego-based leader in genetic-sequencing equipment. An acquirer looking for innovation would have been likelier to try to buy Gateway, a company that is almost an after-thought now. billion tender offer directly to shareholders.

Innovation 13

Innovation Company Biotechnology CFO 13

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

MAY 26, 2016

While a dynamic, competitive economy rewards innovative firms with high profits and punishes poor performers with low profits, sustained aggregate profits suggest, instead, that firms are able to get away with higher prices because competition is limited. If so, then high profits portend diminished productivity growth.

Pharmaceuticals 14

Pharmaceuticals Politics Price Chemicals 14

Harvard Business Review

AUGUST 9, 2012

Selling pharmaceuticals in Latin America is not the same as selling them in the United States or Western Europe. So if a doctor prescribes a medication priced at 100 pesos, that is what it will cost the patient. So if a doctor prescribes a medication priced at 100 pesos, that is what it will cost the patient.

Pharmaceuticals 14

Pharmaceuticals Strategy Advertising Price 14

Harvard Business Review

MAY 20, 2014

In pharmaceuticals, the largest company, Pfizer, is the result of decades of mergers. The current corporate entity is comprised of firms that used to be called: King Pharmaceuticals, Wyeth, American Cyanamid, Lederle, Pharmacia, Upjohn, Searle, SUGEN, Warner-Lambert, Parke-Davis and others.

Pharmaceuticals 14

Pharmaceuticals Banking Chemicals Trends 14

Harvard Business Review

JANUARY 31, 2013

Second, we see a raft of innovations that will alter how products are designed, manufactured and sold — everything from nanotechnologies to 3D printing. Then, manufacturing's most important role is as a driver of innovation, trade, and productivity. Innovations Are Changing The Way We Design Products.

Globalization 11

Globalization Supply Chain Pharmaceuticals McKinsey 11

Harvard Business Review

MARCH 27, 2018

.” But absent “demonstrable harm to competition and consumers,” the DOJ is “reluctant to impose special duties on digital platforms, out of [its] concern that special duties might stifle the very innovation that has created dynamic competition for the benefit of consumers.” ” How Data-opolies Harm.

Company 14

Company Advertising Incentives Engineering 14

Harvard Business Review

MAY 17, 2012

Enter jugaad innovation — a cost-effective approach for creating affordable products and services using limited resources. Realizing that their customers were doctors and parents in villages, they set out to identify the product features that would bring the most value to these rural users.

Incubator 12

Incubator Business Model Entrepreneur Cost 12

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

APRIL 2, 2018

There is an abundance of high-quality comparative effectiveness data for pharmaceuticals, largely because of the drug approval process, but there’s less data on the value of other expensive investments into health, such as doctor visits and hospitalizations. (For

Health Care 8

Health Care Insurance Pharmaceuticals Incentives 8

Harvard Business Review

JUNE 16, 2011

So it is with most breakthrough innovations and banner financial years. Investors grapple daily in an effort to figure out how to value companies whose accounting assets — things like land, capital, products, and licenses — don't adequately express their true market value. If ego and time allow, the list can be quite long.

Intangible Assets 16

Intangible Assets Analysis Pharmaceuticals Innovation 16

Harvard Business Review

SEPTEMBER 5, 2016

Pearson, the educational publisher, measures the efficacy of its products to improve educational outcomes. Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. ” Health care. ” Health care. Making PbR Work.

Incentives 8

Incentives Health Care Education Insurance 8

Strategy Driven

MARCH 18, 2011

PL and CM: Coherent companies – those that possess a capabilities system that aligns their strategy with their product/service portfolio – generate superior performance over time, which is what we call the coherence premium. SD : What is the ‘coherence premium?’. SD : What does it mean to have a ‘right to win?’.

Resources 51

Resources Industry System Strategy 51

Harvard Business Review

NOVEMBER 27, 2013

Recent events have seen a rash of the departures from large corporates: Steve Ballmer from MicroSoft, Jeremy Levin from Teva Pharmaceutical, and Thorsten Heins from Blackberry. After the initial rush of enthusiasm and energy, established routines and networks can smother the drive for innovation.

CEO 15

CEO Long-term Welch Pharmaceuticals 15

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. Innovation, customization, speed, and location are also among the opportunities it offers. For example, printing products on demand would significantly reduce the U.S. trillion in inventories held by U.S.

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

DECEMBER 14, 2017

To be the change that many desire, these new mergers and acquisitions, and the others that will likely follow, must produce a higher-quality product for consumers (and satisfy physicians and other health professionals) at an affordable price. Both CVS’s planned $69 billion acquisition of Aetna and UnitedHealth’s $4.9

Health Care 8

Health Care System Insurance Pharmaceuticals 8

Harvard Business Review

DECEMBER 18, 2014

Since that first foray into negotiating lower prices for commodity items, these coalitions have expanded their reach to include aggregation of supply purchases of items such as implantable medical devices, as well as drugs, capital purchases like CAT scan equipment and even electricity.

Health Care 9

Health Care Retail Mayo Pharmaceuticals 9

Harvard Business Review

FEBRUARY 4, 2013

Our research with members of the global C-suite, and with leading sustainability and innovation experts, has identified seven vectors of breakthrough change. Levi Strauss, intriguingly, has used biomimetic techniques in developing new production techniques for jeans. Business would change the rules of the game. Breakthrough Science.

EPS 9

EPS Innovation CEO Pharmaceuticals 9

Harvard Business Review

OCTOBER 26, 2011

In the last year, however, early-stage investments in clean energy production technologies have fallen substantially (see the table at the end of this piece for more detail). Despite these gloomy headlines, three developments in the sector give us hope that the revolution in clean energy production is far from dead: 1.

Energy 11

Energy Finance IPO Biotechnology 11

Harvard Business Review

MAY 16, 2011

True collaboration always has open-ended elements — ranging from precisely how new innovations will be implemented, to how products will fare in the market, and even to what priorities partners will pursue in the face of changes in the environment. Google uses a different approach to working with multiple external parties.

Software 18

Software Licensing Long-term Telecommunications 18

Harvard Business Review

FEBRUARY 20, 2014

Whereas we’ve been growing our manufacturing sector since the ’60s in terms of product volumes and dollar output, manufacturing employment hasn’t grown at all. Since then, America’s productivity lead has been growing sharply, not falling behind. This may all change as China innovates and grows. Chinese factory workers.

Intellectual Capital 9

Intellectual Capital Magazine Pharmaceuticals Creativity 9

Harvard Business Review

MARCH 11, 2018

That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. “Japanese leaders recognize the importance of encouraging medical innovation,” Eli Lilly and Co. Older people need more medicine.

Pharmaceuticals 8

Pharmaceuticals Health Care Industry Content 8

Harvard Business Review

SEPTEMBER 20, 2013

Content Innovation. For example, a product evaluating nonprofit organizations may be highly useful to a wealth manager seeking to help his client to select a charity as part of a value-added tax efficiency service. Consider comparable offerings from competition and their pricing structure. In some cases, they’re right.

Execution 9

Execution Metrics Content Christensen 9

Harvard Business Review

FEBRUARY 11, 2016

Google and Intel rely on experts in social science and biomechanics to develop transformative products by better understanding how people think about and use technology. And in these discussions, most executives acknowledge the tendency to send mixed signals and the impact on the productivity and commitment of external resources.

Agility 8

Agility Organization Resources Fixed Costs 8

Harvard Business Review

SEPTEMBER 7, 2015

In each simulated time period, the player makes strategic decisions and receives feedback from past decisions—on how fast to grow, how to set prices, or how aggressively to advertise. Hiring policies influence morale, productivity and turnover, marketing efforts shape demand growth, and competitors fight back.

Seminar 8

Seminar Learning Curve Strategy Comparison 8

Harvard Business Review

SEPTEMBER 4, 2015

Innovation is widely regarded as important to long-term business performance. However, CEOs often don’t have the career background and education that would equip them to personally lead the process of new product development. The data captured a 20-year period, from 1995 to 2014. Overall, it is a messy picture.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

NOVEMBER 2, 2018

That means that to control costs going forward, employers may have to confront the true underlying causes of rising health care expenditures: high prices and health care inefficiencies. The first is that health care providers charge employers very high prices — way higher than those paid by public insurers like Medicare and Medicaid.

Health Care 8

Health Care Cost Insurance Price 8

Harvard Business Review

OCTOBER 24, 2014

Here are some of the challenges that I’ve observed: Product management. Successful IoT plays require more than simply adding connectivity to a product and charging for service — something many companies don’t immediately understand. When product-based companies add services and connectivity, operational requirements increase.

Productivity 10

Productivity Products Company Engineering 10

Harvard Business Review

SEPTEMBER 20, 2011

A vast ideological gap on macro-economic policy divides Washington and much of the nation, but there is almost universal agreement on one solution: innovation. Innovation is now perceived as a panacea for job creation, income generation, economic growth, dollar strength, and the revival of the U.S. as global hegemon.

Innovation 13

Innovation Supply Chain Offshoring Policies 13

Harvard Business Review

NOVEMBER 12, 2018

Indeed, Novartis recently said that its life-saving gene therapy for spinal muscular atrophy would be “cost-effective” at $4 million to $5 million – hinting at the pricing the company has in mind. These new therapies could face a similar fate if prices can’t be brought down. Something has got to give.

Business Model 14

Business Model Insurance Cost Bond 14

Harvard Business Review

NOVEMBER 28, 2017

One of your executives comes to you with a proposal: she wants to lower the quality of service at the restaurants, reduce product safety standards, use deceptive marketing practices, lower employee pay, and adopt worse environmental practices. Imagine you’re the CEO of a casual dining chain. But these effects were limited.

Company 8

Company Short-term Long-term Price 8

Harvard Business Review

SEPTEMBER 5, 2016

Yet there’s compelling evidence that bureaucracy creates a significant drag on productivity and organizational resilience and innovation. The facility is more than twice as productive as its sister plants in GE Aviation. million individuals for other work that is more creative and productive.

Cost 8

Cost Bureaucracy GDP Management 8

Harvard Business Review

NOVEMBER 20, 2015

One result is that they keep their cards close to their chests about what they are looking for (at first), while expecting you to reveal everything – your finances, pricing, ownership, human resources, production processes, quality assurance, customer service procedures, KPIs, and existing customers.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

FEBRUARY 6, 2018

Consider its decision to pursue the market for pharmaceutical distribution, or the recent announcement that it will be teaming up with Berkshire Hathaway and JP Morgan Chase to create joint solutions for reducing the health care spending of more than 1 million employees and their families.

Health Care 13

Health Care Retail Operations Insurance 13